Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 2/20 | 0.31 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20562388 | 0.85 | MAPT (0.36) | MAPTMEN1HTTKMT2ALMNA | |
| SCHEMBL3279036 | 0.79 | HTR2A (0.41) | MAPTMEN1HTTKMT2ALMNA | |
| SCHEMBL8715944 | 0.78 | NOTUM (0.39) | MAPTLMNANOTUMHTR2AHTR2C | |
| SCHEMBL1526163 | 0.76 | KDM4E (0.33) | MAPTMEN1KMT2ALMNARAB9A | |
| SCHEMBL1028624 | 0.76 | GAA (0.31) | GAAHTR2AHTR2C | |
| SCHEMBL10829023 | 0.76 | HTR2A (0.41) | MAPTMEN1HTTKMT2ALMNA | |
| SCHEMBL2348836 | 0.75 | MAPT (0.32) | MAPTHTTHTR2AHTR2CRAB9A | |
| SCHEMBL15063988 | 0.74 | NOTUM (0.33) | NOTUMRAPGEF4IDO1 | |
| SCHEMBL219318 | 0.72 | GAA (0.42) | MAPTMEN1KMT2AGAARAB9A | |
| SCHEMBL5566940 | 0.72 | KMT2A (0.33) | MAPTMEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2298311-B1 | w-Carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors | BAYER HEALTHCARE LLC (US) | 2012-05-09 | — | — | EP | claimed |
| US-20120009150-A1 | DIARYL UREAS FOR TREATING VIRUS INFECTIONS | WEBER OLAF (DE) | 2012-01-12 | — | — | US | claimed |
| EP-1158985-B1 | OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS | BAYER HEALTHCARE LLC (US) | 2011-12-28 | — | — | EP | claimed |
| US-20110263657-A1 | DIARYL UREAS FOR TREATING HEART FAILURE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-10-27 | — | — | US | claimed |
| US-20110158942-A1 | DIARYL UREAS FOR TREATING VIRUS INFECTIONS | WEBER OLAF | 2011-06-30 | — | — | US | claimed |
| EP-2338488-A1 | Drug combinations with substituted diaryl ureas for the treatment of cancer | Bayer HealthCare, LLC (US) | 2011-06-29 | — | — | EP | claimed |
| CN-102076338-A | Diaryl ureas for the treatment of heart failure | BAYER SCHERING PHARMA AG | 2011-05-25 | — | — | CN | claimed |
| EP-2298311-A1 | w-Carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors | Bayer Healthcare Llc (US) | 2011-03-23 | — | — | EP | claimed |
| EP-2293792-A1 | DIARYL UREAS FOR TREATING HEART FAILURE | Bayer Schering Pharma Aktiengesellschaft (DE) | 2011-03-16 | — | — | EP | claimed |
| EP-1948176-B1 | DIARYL UREAS FOR TREATING PULMONARY HYPERTENSION | BAYER SCHERING PHARMA AG (DE) | 2011-01-05 | — | — | EP | claimed |
| US-20020042517-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER CORPORATION | 2002-04-11 | — | — | US | claimed |
| EP-1158985-A1 | OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS | Bayer Corporation (US) | 2001-12-05 | — | — | EP | claimed |
| US-20010034447-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-10-25 | — | — | US | claimed |
| EP-1140840-A1 | -G(V)-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | Bayer Corporation (US) | 2001-10-10 | — | — | EP | claimed |
| US-20010027202-A1 | Omega-carboxyaryl substituted disphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-10-04 | — | — | US | claimed |
| US-20010016659-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-08-23 | — | — | US | claimed |
| US-20010011135-A1 | Omega-carboxyaryl subsituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-08-02 | — | — | US | claimed |
| US-20010011136-A1 | omega-carboxyyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-08-02 | — | — | US | claimed |
| WO-2000041698-A1 | φ-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS | BAYER CORPORATION (US) | 2000-07-20 | — | — | WO | claimed |
| WO-2000042012-A1 | φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BAYER CORPORATION (US) | 2000-07-20 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120009150-A1 | DIARYL UREAS FOR TREATING VIRUS INFECTIONS | UBA6, MCM6, UBQLN1 | MAPT 703/4885MEN1 3312/4885HTT 1708/4885 |
| US-20010011135-A1 | Omega-carboxyaryl subsituted diphenyl ureas as raf kinase inhibitors | BRAF, RAF1, ARAF | MAPT 2180/4885MEN1 4453/4885HTT 2682/4885 |
| US-20010011136-A1 | omega-carboxyyaryl substituted diphenyl ureas as raf kinase inhibitors | BRAF, ARAF, RAF1 | MAPT 2754/4885MEN1 4280/4885HTT 3133/4885 |
| US-20010034447-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BRAF, RAF1, ARAF | MAPT 2299/4885MEN1 4567/4885HTT 3005/4885 |
| US-20010016659-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BRAF, RAF1, ARAF | MAPT 2299/4885MEN1 4567/4885HTT 3005/4885 |
| US-20110263657-A1 | DIARYL UREAS FOR TREATING HEART FAILURE | UBA6, UBQLN1, UHRF1 | MAPT 1851/4885MEN1 4024/4885HTT 898/4885 |
| US-20010027202-A1 | Omega-carboxyaryl substituted disphenyl ureas as raf kinase inhibitors | BRAF, NRAS, ARAF | MAPT 2928/4885MEN1 3519/4885HTT 2949/4885 |
| US-20110158942-A1 | DIARYL UREAS FOR TREATING VIRUS INFECTIONS | UBA6, MCM6, UBQLN1 | MAPT 703/4885MEN1 3312/4885HTT 1708/4885 |
| US-20020042517-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BRAF, RAF1, ARAF | MAPT 2299/4885MEN1 4567/4885HTT 3005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.